XENE
HEALTHCAREXenon Pharmaceuticals Inc
AI Insight
What's Moving XENE Today?
No stock-specific AI insight has been generated for XENE yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$30.00$63.95
$54.61
Fundamentals
Market Cap$5.1B
P/E Ratio—
EPS$-4.70
Dividend Yield—
Dividend / Share—
ROE-37.5%
Profit Margin—
Debt / Equity—
Trading
Volume1.5M
Avg Volume (10D)—
Shares Outstanding96.7M
XENE News
23 articles- Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's WhyYahoo Finance·Jun 23, 2026
- Assessing Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Pullback And Modest Undervaluation EstimateYahoo Finance·Jun 11, 2026
- UPGUYS Founders Mat Rezaei and Ramin Behzadi Named 2026 EY Entrepreneur Of The Year® Pacific Region Finalists as Canada's Leading TRT Platform Scales NationwideYahoo Finance·Jun 9, 2026
- [144] Xenon Pharmaceuticals Inc. SEC FilingStock Titan·Jun 5, 2026
- Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 29, 2026
- JPMorgan Raises its Price Target on Xenon Pharmaceuticals (XENE)Yahoo Finance·May 23, 2026
- What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA FilingMotley Fool·May 18, 2026
- Driehaus files Schedule 13G/A disclosing 4.87% in Xenon (XENE)Stock Titan·May 15, 2026
- SCANBO® FEATURED IN GOVERNMENT OF BRITISH COLUMBIA'S 2026 LIFE SCIENCES ECOSYSTEM MAPYahoo Finance·May 12, 2026
- A Look At Xenon Pharmaceuticals (XENE) Valuation After Phase 3 X TOLE2 Success And Extended Cash RunwayYahoo Finance·May 11, 2026
- Did Positive X-TOLE2 Data and a Major Cash Raise Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative?Yahoo Finance·May 11, 2026
- Xenon Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 9, 2026
- Xenon Q1 Earnings Match Estimates, Pipeline Development in FocusYahoo Finance·May 8, 2026
- Xenon (XENE) Q1 2026 Earnings TranscriptMotley Fool·May 7, 2026
- Xenon Reports Q1 2026 Financial Results and Provides Business UpdateYahoo Finance·May 7, 2026
- X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 6, 2026
- Three Finalists Announced for the 2026 Bloom Burton AwardYahoo Finance·May 1, 2026
- Xenon to Report Q1 2026 Financial Results on May 7, 2026Yahoo Finance·Apr 30, 2026
- KCNQ2 Developmental and Epileptic Encephalopathy Market Research Report 2025-2035, Competitive Analysis of Biohaven, Xenon Pharma, Lundbeck, Praxis Precision Medicines, NeuShen TherapeuticsYahoo Finance·Apr 28, 2026
- Xenon Pharmaceuticals Highlights Strong Phase III Azetukalner Data, Q3 NDA Plans at Bloom Burton ConferenceMarketbeat·Apr 26, 2026
- Xenon Pharmaceuticals Inc (XENE) Looking At a $2 Billion Opportunity HereYahoo Finance·Apr 23, 2026
- Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual MeetingGlobeNewswire Inc.·Apr 19, 2026
- Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should KnowThe Motley Fool·Mar 27, 2026
All 23 articles loaded
Price Data
Open$54.62
Previous Close$54.79
Day High$55.47
Day Low$54.12
52 Week High$63.95
52 Week Low$30.00
52-Week Range
$30.00$63.95
$54.61
Fundamentals
Market Cap$5.1B
P/E Ratio—
EPS$-4.70
Dividend Yield—
Dividend / Share—
ROE-37.5%
Profit Margin—
Debt / Equity—
Trading
Volume1.5M
Avg Volume (10D)—
Shares Outstanding96.7M
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders in Canada. The company is headquartered in Burnaby, Canada.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—